IPP Bureau
Artemis Hospitals opens new centre Daffodils by Artemis in Jaipur
By IPP Bureau - September 06, 2022
Daffodils by Artemis is a premiere luxury birthing centre offering mother and child care services.
InnoCare announces priority review of Orelabrutinib for the treatment of R/R MZL by NMPA
By IPP Bureau - September 06, 2022
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
Balaxi Pharma to issue Rs. 49.61 crore Equity Shares/Warrants
By IPP Bureau - September 06, 2022
Proceeds from the proposed issue will be utilized to part finance Balaxi’s planned EU GMP-compliant manufacturing facility for Oral Solid Dosages and Liquid Injectables at TSIIC Pharma Formulations SEZ
Aurionpro acquires US based startup Hello Patients
By IPP Bureau - September 06, 2022
Hello Patients provides healthcare billing and patients’ management solution
AstraZeneca partners with Alveofit to scale up the diagnosis and treatment of lung diseases in India
By IPP Bureau - September 05, 2022
This partnership aims to embed latest technological advancements in diagnosing and managing lung disorders and associated non-communicable diseases like asthma, pulmonary fibrosis and COPD.
Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.1-adapted bivalent COVID-19 vaccine booster in EU
By IPP Bureau - September 05, 2022
CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine
Yingli Pharma announces first patient dosed in Phase 2 Trial of Linperlisib for peripheral T Cell Lymphoma
By IPP Bureau - September 05, 2022
Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma
Dr. Mandaviya emphasizes on ‘Jan Bhagidari’ to popularise organ donation
By IPP Bureau - September 05, 2022
The purpose of the conclave was to discuss the present situation of body-organ-eye donation in India and find solutions to the challenges ahead in future
Ginkgo Bioworks appoints Dr. Behzad Mahdavi as Sr. VP of Biopharma Manufacturing & Life Science Tools
By IPP Bureau - September 03, 2022
Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities.
USFDA approves first treatment option for generalized pustular psoriasis flares in adults
By IPP Bureau - September 03, 2022
Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares
Ashland to expand bioresorbable polymers capacity in Ireland
By IPP Bureau - September 02, 2022
The capital expansion program commenced in June 2022 and is expected to complete in 2024
Centre grants approval of three Bulk Drug Parks
By IPP Bureau - September 02, 2022
The Bulk Drug Parks to be developed under the scheme will provide common infrastructure facilities at one place thereby creating a robust ecosystem for the bulk drug manufacturing in the country and also reducing manufacturing cost significantly
Infosys completes acquisition of BASE life science
By IPP Bureau - September 02, 2022
The acquisition reaffirms Infosys’ commitment to help global life sciences companies
NATCO Pharma to sell stake in Nativita and assets of Pharma division
By IPP Bureau - September 02, 2022
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
Kimia Biosciences unveils new logo, new website
By IPP Bureau - September 02, 2022
